Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis

Abstract Introduction Despite advancements in the treatment of psoriasis (PsO), there are few head-to-head studies assessing comparative effectiveness of the newest therapies approved to treat PsO. Our objective was to assess the comparative clinical effectiveness of risankizumab and deucravacitinib...

Full description

Saved in:
Bibliographic Details
Main Authors: April W. Armstrong, Ahmed M. Soliman, Paolo Gisondi, Siran Fang, Manish Patel, Bruce Strober
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-10-01
Series:Dermatology and Therapy
Subjects:
Online Access:https://doi.org/10.1007/s13555-024-01293-y
Tags: Add Tag
No Tags, Be the first to tag this record!